Nifty
Sensex
:
:
11504.95
38845.82
-11.15 (-0.10%)
-134.03 (-0.34%)

Pharmaceuticals & Drugs - Global

Rating :
52/99

BSE: 506690 | NSE: UNICHEMLAB

258.90
18-Sep-2020
  • Open
  • High
  • Low
  • Previous Close
  •  267.00
  •  271.95
  •  253.65
  •  264.20
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  139317
  •  370.38
  •  304.70
  •  80.00

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 1,819.64
  • N/A
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 1,769.86
  • 1.55%
  • 0.72

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.93%
  • 3.64%
  • 30.23%
  • FII
  • DII
  • Others
  • 1.61%
  • 8.74%
  • 4.85%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 3.92
  • -1.90
  • -4.27

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • -
  • -
  • -

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.40
  • 24.43
  • -

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 0.46
  • 0.46
  • 0.46

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 18.25
  • 23.23
  • 28.55

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 20
Jun 19
Var%
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Net Sales
317.27
297.74
6.56%
320.23
374.24
-14.43%
0.00
0.00
0
295.61
261.15
13.20%
Expenses
305.19
317.95
-4.01%
306.87
350.81
-12.53%
0.00
0.00
0
322.41
315.12
2.31%
EBITDA
12.08
-20.22
-
13.36
23.44
-43.00%
0.00
0.00
0
-26.81
-53.97
-
EBIDTM
3.81%
-6.79%
4.17%
6.26%
0.00%
0.00%
-9.07%
-20.66%
Other Income
16.71
26.26
-36.37%
11.82
20.71
-42.93%
0.00
0.00
0
28.13
31.64
-11.09%
Interest
1.25
1.28
-2.34%
2.40
2.84
-15.49%
0.00
0.00
0
1.86
1.35
37.78%
Depreciation
20.54
18.25
12.55%
22.96
18.51
24.04%
0.00
0.00
0
20.98
16.06
30.64%
PBT
7.00
-13.49
-
-0.17
22.80
-
0.00
0.00
0
-21.51
-39.73
-
Tax
4.61
-7.53
-
17.63
-9.01
-
0.00
0.00
0
0.68
-1.75
-
PAT
2.39
-5.96
-
-17.80
31.82
-
0.00
0.00
0
-22.19
-37.98
-
PATM
0.75%
-2.00%
-5.56%
8.50%
0.00%
0.00%
-7.51%
-14.55%
EPS
0.34
-0.85
-
-2.53
4.52
-
0.00
0.00
0
-3.15
-5.40
-

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Net Sales
-
1,210.62
1,188.19
1,379.90
1,540.06
1,332.65
1,201.79
1,133.45
1,080.80
875.46
824.04
Net Sales Growth
-
1.89%
-13.89%
-10.40%
15.56%
10.89%
6.03%
4.87%
23.46%
6.24%
 
Cost Of Goods Sold
-
308.19
364.19
274.97
188.77
386.97
378.57
332.84
343.06
278.55
237.98
Gross Profit
-
902.43
823.99
1,104.93
1,351.28
945.67
823.23
800.61
737.75
596.91
586.07
GP Margin
-
74.54%
69.35%
80.07%
87.74%
70.96%
68.50%
70.63%
68.26%
68.18%
71.12%
Total Expenditure
-
1,261.44
1,269.21
1,358.21
1,357.62
1,168.77
1,100.79
955.75
910.06
759.42
674.08
Power & Fuel Cost
-
73.02
76.39
49.23
41.62
38.25
39.39
35.97
31.36
26.22
22.50
% Of Sales
-
6.03%
6.43%
3.57%
2.70%
2.87%
3.28%
3.17%
2.90%
2.99%
2.73%
Employee Cost
-
273.28
239.32
200.64
169.04
255.92
223.20
187.37
164.88
140.06
123.99
% Of Sales
-
22.57%
20.14%
14.54%
10.98%
19.20%
18.57%
16.53%
15.26%
16.00%
15.05%
Manufacturing Exp.
-
151.01
136.15
125.30
103.70
150.54
145.03
137.05
119.15
101.54
102.67
% Of Sales
-
12.47%
11.46%
9.08%
6.73%
11.30%
12.07%
12.09%
11.02%
11.60%
12.46%
General & Admin Exp.
-
228.99
239.66
594.53
744.66
167.66
153.29
127.77
104.73
88.54
79.74
% Of Sales
-
18.92%
20.17%
43.09%
48.35%
12.58%
12.76%
11.27%
9.69%
10.11%
9.68%
Selling & Distn. Exp.
-
223.02
197.24
108.38
107.77
166.84
157.12
134.03
135.93
116.00
106.52
% Of Sales
-
18.42%
16.60%
7.85%
7.00%
12.52%
13.07%
11.82%
12.58%
13.25%
12.93%
Miscellaneous Exp.
-
3.93
16.26
5.16
2.06
2.58
4.19
0.73
10.97
8.50
106.52
% Of Sales
-
0.32%
1.37%
0.37%
0.13%
0.19%
0.35%
0.06%
1.01%
0.97%
0.08%
EBITDA
-
-50.82
-81.02
21.69
182.44
163.88
101.00
177.70
170.74
116.04
149.96
EBITDA Margin
-
-4.20%
-6.82%
1.57%
11.85%
12.30%
8.40%
15.68%
15.80%
13.25%
18.20%
Other Income
-
91.31
98.41
3,278.19
5.50
19.11
20.72
42.38
16.96
12.50
8.32
Interest
-
7.85
7.52
8.01
3.36
2.90
3.04
3.19
3.29
4.08
2.39
Depreciation
-
81.67
67.37
50.51
43.52
38.79
41.27
45.72
38.34
30.43
29.22
PBT
-
-49.02
-57.50
3,241.36
141.07
141.31
77.41
171.17
146.07
94.03
126.66
Tax
-
11.97
-33.64
696.23
32.58
29.30
2.13
43.00
32.85
22.77
31.68
Tax Rate
-
-24.42%
58.50%
21.48%
23.09%
21.27%
2.75%
25.12%
22.49%
24.22%
25.01%
PAT
-
-61.00
-23.87
2,545.13
108.49
108.48
75.28
128.16
113.23
71.26
94.98
PAT before Minority Interest
-
-61.00
-23.87
2,545.13
108.49
108.48
75.28
128.16
113.23
71.26
94.98
Minority Interest
-
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
-
-5.04%
-2.01%
184.44%
7.04%
8.14%
6.26%
11.31%
10.48%
8.14%
11.53%
PAT Growth
-
-
-
2,245.96%
0.01%
44.10%
-41.26%
13.19%
58.90%
-24.97%
 
EPS
-
-8.66
-3.39
361.52
15.41
15.41
10.69
18.20
16.08
10.12
13.49

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Shareholder's Funds
2,531.35
2,619.91
2,680.08
1,063.62
954.33
867.52
816.61
727.07
660.58
617.70
Share Capital
14.08
14.08
14.07
18.18
18.17
18.15
18.13
18.09
18.06
18.05
Total Reserves
2,512.44
2,601.99
2,665.42
1,044.00
935.01
848.52
797.74
707.98
641.80
598.85
Non-Current Liabilities
43.72
10.10
46.46
64.49
76.02
74.21
97.72
94.31
92.67
87.44
Secured Loans
0.00
0.00
0.33
0.44
22.98
20.35
24.65
20.89
20.47
19.01
Unsecured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
23.49
22.72
Long Term Provisions
23.51
14.60
10.76
25.33
12.58
8.88
7.64
9.19
10.24
7.90
Current Liabilities
566.73
502.92
463.51
392.62
275.09
211.76
230.32
251.12
233.30
176.15
Trade Payables
250.22
221.41
226.23
210.73
163.95
138.23
150.52
156.63
140.30
109.99
Other Current Liabilities
122.04
68.45
63.03
68.01
60.56
45.86
32.99
36.65
34.28
26.00
Short Term Borrowings
184.03
199.67
150.29
97.62
12.93
1.63
1.04
6.17
25.42
9.04
Short Term Provisions
10.44
13.39
23.97
16.25
37.65
26.05
45.78
51.67
33.30
31.13
Total Liabilities
3,141.80
3,132.93
3,190.05
1,520.73
1,305.44
1,153.49
1,144.65
1,072.50
986.55
881.29
Net Block
866.06
806.29
574.45
487.22
402.60
415.99
419.29
447.76
408.39
377.31
Gross Block
1,103.64
975.96
689.74
561.37
439.53
724.65
688.25
675.87
599.27
537.04
Accumulated Depreciation
237.59
169.67
115.29
74.15
36.92
308.66
268.96
228.11
190.87
159.73
Non Current Assets
1,455.33
1,093.64
853.59
772.27
673.34
589.07
563.97
594.06
547.20
456.50
Capital Work in Progress
330.47
92.39
238.15
249.98
237.13
122.64
90.54
132.20
112.76
62.87
Non Current Investment
134.38
129.20
9.20
9.51
5.54
5.83
5.72
5.72
0.03
0.03
Long Term Loans & Adv.
112.90
56.37
24.05
25.57
28.05
44.61
48.42
8.38
26.02
16.29
Other Non Current Assets
11.52
9.39
7.74
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Current Assets
1,686.47
2,039.29
2,336.47
748.46
632.11
564.42
580.68
478.44
439.35
424.79
Current Investments
419.10
800.75
895.55
8.00
8.04
35.04
5.67
33.06
14.50
21.29
Inventories
396.54
338.66
272.86
281.71
230.57
207.68
203.49
143.05
157.96
150.26
Sundry Debtors
390.14
436.05
276.92
315.32
220.09
191.58
196.51
206.95
183.25
185.13
Cash & Bank
233.81
200.99
681.46
16.14
20.13
26.96
52.15
24.64
23.23
15.16
Other Current Assets
246.88
68.65
64.17
28.49
153.28
103.17
122.86
70.75
60.40
52.95
Short Term Loans & Adv.
183.04
194.18
145.51
98.80
122.77
82.25
105.67
61.73
53.14
47.14
Net Current Assets
1,119.74
1,536.37
1,872.95
355.84
357.02
352.66
350.36
227.32
206.05
248.65
Total Assets
3,141.80
3,132.93
3,190.06
1,520.73
1,305.45
1,153.49
1,144.65
1,072.50
986.55
881.29

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Cash From Operating Activity
19.82
-327.77
-112.34
68.19
111.91
78.10
86.73
171.23
124.08
68.59
PBT
-48.21
-57.44
3,241.14
141.25
137.68
77.41
171.17
146.07
94.03
126.66
Adjustment
18.79
6.80
-3,207.66
53.31
39.65
35.57
18.74
47.15
39.37
27.54
Changes in Working Capital
53.58
-264.94
-146.67
-98.65
-34.16
-16.49
-66.32
13.05
13.51
-54.81
Cash after chg. in Working capital
24.15
-315.57
-113.20
95.91
143.16
96.49
123.58
206.27
146.91
99.39
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-4.34
-12.20
0.86
-27.72
-31.25
-18.39
-36.85
-35.04
-22.83
-30.81
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-41.21
-286.01
1,648.33
-127.87
-85.33
-52.34
35.70
-118.45
-101.80
-47.60
Net Fixed Assets
-338.73
-139.02
-107.71
-135.60
154.89
-73.58
38.14
-92.98
-106.47
-67.03
Net Investments
374.24
-63.59
-889.36
17.40
42.09
-32.73
20.34
-34.14
-5.98
28.17
Others
-76.72
-83.40
2,645.40
-9.67
-282.31
53.97
-22.78
8.67
10.65
-8.74
Cash from Financing Activity
-62.30
-2.42
-881.13
59.23
-33.42
-50.95
-94.92
-51.38
-14.21
-29.46
Net Cash Inflow / Outflow
-83.69
-616.19
654.86
-0.46
-6.84
-25.19
27.51
1.41
8.07
-8.48
Opening Cash & Equivalents
197.05
666.07
11.21
11.67
26.96
52.15
24.64
23.23
15.16
23.64
Closing Cash & Equivalent
226.22
197.05
666.07
11.21
20.13
26.96
52.15
24.64
23.23
15.16

Financial Ratios

Consolidated /

Standalone
Description
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Book Value (Rs.)
358.85
371.69
380.95
116.88
104.93
95.48
90.02
80.27
73.06
68.36
ROA
-1.94%
-0.75%
108.06%
7.68%
8.82%
6.55%
11.56%
11.00%
7.63%
11.31%
ROE
-2.37%
-0.90%
136.04%
10.77%
11.92%
8.95%
16.62%
16.34%
11.16%
16.11%
ROCE
-1.49%
-1.77%
162.77%
13.42%
14.97%
9.29%
21.84%
20.13%
14.03%
20.37%
Fixed Asset Turnover
1.16
1.43
2.21
3.08
2.32
1.71
1.67
1.71
1.55
1.66
Receivable days
124.55
109.51
78.30
63.41
55.72
58.55
64.53
65.42
76.34
77.46
Inventory Days
110.83
93.93
73.33
60.67
59.32
62.03
55.42
50.47
63.88
56.72
Payable days
74.71
74.09
94.97
104.25
52.00
52.61
62.52
65.77
65.64
63.82
Cash Conversion Cycle
160.67
129.34
56.65
19.82
63.05
67.97
57.43
50.11
74.58
70.36
Total Debt/Equity
0.07
0.08
0.06
0.09
0.04
0.03
0.03
0.04
0.11
0.08
Interest Cover
-5.25
-6.64
405.79
43.00
48.57
26.45
54.66
45.40
24.06
53.94

News Update:


  • Unichem Laboratories calls for measures to step up local production of raw materials
    10th Aug 2020, 14:07 PM

    The ongoing coronavirus pandemic calls for concentrated efforts to build upon capacities for active pharmaceutical ingredients in the country

    Read More
  • Unichem Laboratories gets ANDA's approval for Tolterodine Tartrate tablets
    6th Aug 2020, 14:24 PM

    The product will be commercialized from Unichem’s Goa plant

    Read More
  • Unichem Laboratories turns black in Q1
    5th Aug 2020, 10:18 AM

    Total income of the company increased by 11.52% at Rs 333.98 crore for Q1FY21

    Read More
  • Unichem Lab - Quarterly Results
    4th Aug 2020, 16:47 PM

    Read More
  • Unichem Laboratories receives ANDA approval for Amiodarone Tablets
    22nd Jul 2020, 13:06 PM

    The product will be commercialized from Unichem’s Ghaziabad Plant

    Read More
  • Unichem Lab secures ANDA's nod for Baclofen Tablets
    10th Jul 2020, 14:35 PM

    Baclofen Tablets are indicated for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis

    Read More
  • Unichem Lab secures ANDA's nod for Cyclobenzaprine Hydrochloride Tablets
    7th Jul 2020, 14:52 PM

    Cyclobenzaprine HCI Tablets are indicated for the treatment as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.